Strong pipeline of highly differentiated products

The Lead Discovery Center GmbH (LDC) is working on a broad portfolio of drug discovery projects, small molecules and therapeutic antibodies. The indications include cancer and metabolic syndromes, neurodegenerative diseases, rare diseases, inflammatory disorders and infections, as well as other conditions with high, unmet clinical needs.

 
Disease Areas
Development Stage
active licensed/partnered startup
 
TARGET
HIT
LEAD
CANDIDATE
MARKET
TARGET
HIT
LEAD
CANDIDATE
CLINIC
target ID
target validation
assay development
screening
hit-to-lead conversion
lead-to-candidate conversion
PD
PH1
PH2
PH3
eCYCLOPHILINS
NET FORMATION INHIBITORS
GRK5
SLC6A15
GPR81
P2Y6
GLUT
NATA
TRPC4/5
HEDHEHOG
GFAT
CDK12/13
NP-DERIVED ENZYME INHIBITORS
CYTOLYSIN
RIST
ASPA
WWC1/2
EPHRIN B2
KRAS/PDEd STAB
PDX1
KINSUB
GCN2
MIVAKA
AMT
TTLL, CCP
PD DEMENTIA
HTRA1
SFRP1
NTNU1
IRE1/ERAAT
DRAXIN
SIRT7
RHO GEF
PLEXIN B1 SEMA 4D
NOTCH
BECLIN1 AUTOPHAGY
DEG S
LRKK2
LIN28B
STS
P2X7
AK2
14 3 3
NANOCOMBAC
IL11 -AB
KLK8 -AB
FGFR4 - AB
GDF15 - AB
GLI2
CAMKII/HDAC4
FAO
APLK1
ATUVECICLIB
Target 1
Target 2
Target 3
Target 4
Target 5
Target 6
Target 7
Target 8
Target 9
IMMUNE CHECKPOINT
REWIND
QUENCH BIO
PEARL RIVER BIO
QLi5 Therapeutics